CoChat
Sign Up
Cited by 67

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A microRNA Signature Associated with Early Recurrence in Breast Cancer

Pérez-Rivas, Luis G., Jerez, José M., Carmona, Rosario, de Luque, Vanessa, Vicioso, Luis, Claros, M. Gonzalo, Viguera, Enrique, Pajares, Bella, Sánchez, Alfonso, Ribelles, Nuria, Alba, Emilio, Lozano, José·2014·PLoS ONE
DOI 10.1371/journal.pone.0091884PMC PMC3954835
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0091884

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 102

  1. ER Fisher, 1978, Pathological findings from the national surgical adjuvant breast project (Protocol No. 4). IV. Significance of tumor necrosis, Hum Pathol, 9, 523, 10.1016/S0046-8177(78)80133-6 · DOI
  2. CW Elston, 1991, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, 19, 403, 10.1111/j.1365-2559.1991.tb00229.x · DOI
  3. CM Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 · DOI
  4. T Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 98, 10869, 10.1073/pnas.191367098 · DOI
  5. A Spitale, 2009, Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland, Ann Oncol, 20, 628, 10.1093/annonc/mdn675 · DOI
  6. PS Steeg, 2006, Tumor metastasis: mechanistic insights and clinical challenges, Nat Med, 12, 895, 10.1038/nm1469 · DOI
  7. AC Chiang, 2008, Molecular basis of metastasis, N Engl J Med, 359, 2814, 10.1056/NEJMra0805239 · DOI
  8. T Saphner, 1996, Annual hazard rates of recurrence for breast cancer after primary therapy, J Clin Oncol, 14, 2738, 10.1200/JCO.1996.14.10.2738 · DOI
  9. R Demicheli, 1996, Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy, Breast Cancer Res Treat, 41, 177, 10.1007/BF01807163 · DOI
  10. I Jatoi, 2005, Hazard rates of recurrence following diagnosis of primary breast cancer, Breast Cancer Res Treat, 89, 173, 10.1007/s10549-004-1722-0 · DOI
  11. R Demicheli, 2007, Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures, Nat Clin Pract Oncol, 4, 699, 10.1038/ncponc0999 · DOI
  12. R Demicheli, 2007, Comment to "Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and intact primary tumor" by G V Babiera, R Rao, L Feng, F Meric-Bernstam, H M Kuerer, S E Singletary, K K Hunt, M I Ross, K M Gwyn, B W Feig, F C Ames, G N Horthobagyi. Ann Surg Oncol 2006;13:776-782, Ann Surg Oncol, 14, 1519, 10.1245/s10434-006-9279-2 · DOI
  13. R Demicheli, 2008, The effects of surgery on tumor growth: a century of investigations, Ann Oncol, 19, 1821, 10.1093/annonc/mdn386 · DOI
  14. R Demicheli, 2001, Does surgery modify growth kinetics of breast cancer micrometastases?, Br J Cancer, 85, 490, 10.1054/bjoc.2001.1969 · DOI
  15. KR Hess, 2003, Estrogen receptors and distinct patterns of breast cancer relapse, Breast Cancer Res Treat, 78, 105, 10.1023/A:1022166517963 · DOI
  16. R Demicheli, 2010, Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence, Cancer Sci, 101, 826, 10.1111/j.1349-7006.2009.01472.x · DOI
  17. LG Perez-Rivas, 2012, Serum protein levels following surgery in breast cancer patients: a protein microarray approach, Int J Oncol, 41, 2200, 10.3892/ijo.2012.1667 · DOI
  18. A Carlsson, 2011, Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases, Proc Natl Acad Sci U S A, 108, 14252, 10.1073/pnas.1103125108 · DOI
  19. M Pietrowska, 2010, Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer, J Transl Med, 8, 66, 10.1186/1479-5876-8-66 · DOI
  20. R Rouzier, 2005, Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res, 11, 5678, 10.1158/1078-0432.CCR-04-2421 · DOI
  21. TO Nielsen, 2010, A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer, Clin Cancer Res, 16, 5222, 10.1158/1078-0432.CCR-10-1282 · DOI
  22. MC Cheang, 2009, Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer, J Natl Cancer Inst, 101, 736, 10.1093/jnci/djp082 · DOI
  23. MC Cheang, 2008, Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype, Clin Cancer Res, 14, 1368, 10.1158/1078-0432.CCR-07-1658 · DOI
  24. H Kennecke, 2010, Metastatic behavior of breast cancer subtypes, J Clin Oncol, 28, 3271, 10.1200/JCO.2009.25.9820 · DOI · Paper page
  25. JS Parker, 2009, Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, 27, 1160, 10.1200/JCO.2008.18.1370 · DOI
  26. KD Voduc, 2010, Breast cancer subtypes and the risk of local and regional relapse, J Clin Oncol, 28, 1684, 10.1200/JCO.2009.24.9284 · DOI
  27. SJ Dawson, 2013, A new genome-driven integrated classification of breast cancer and its implications, EMBO J, 32, 617, 10.1038/emboj.2013.19 · DOI
  28. DP Bartel, 2009, MicroRNAs: target recognition and regulatory functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002 · DOI · Paper page
  29. S Djuranovic, 2011, A parsimonious model for gene regulation by miRNAs, Science, 331, 550, 10.1126/science.1191138 · DOI
  30. E Lund, 2004, Nuclear export of microRNA precursors, Science, 303, 95, 10.1126/science.1090599 · DOI
  31. P Brodersen, 2009, Revisiting the principles of microRNA target recognition and mode of action, Nat Rev Mol Cell Biol, 10, 141, 10.1038/nrm2619 · DOI
  32. RW Carthew, 2009, Origins and Mechanisms of miRNAs and siRNAs, Cell, 136, 642, 10.1016/j.cell.2009.01.035 · DOI
  33. S Griffiths-Jones, 2008, miRBase: tools for microRNA genomics, Nucleic Acids Res, 36, D154, 10.1093/nar/gkm952 · DOI
  34. CM Croce, 2009, Causes and consequences of microRNA dysregulation in cancer, Nat Rev Genet, 10, 704, 10.1038/nrg2634 · DOI
  35. S Volinia, 2006, A microRNA expression signature of human solid tumors defines cancer gene targets, Proc Natl Acad Sci U S A, 103, 2257, 10.1073/pnas.0510565103 · DOI · Paper page
  36. D Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  37. K Ruan, 2009, MicroRNAs: novel regulators in the hallmarks of human cancer, Cancer Lett, 285, 116, 10.1016/j.canlet.2009.04.031 · DOI
  38. I Grammatikakis, 2013, Modulation of Cancer Traits by Tumor Suppressor microRNAs, Int J Mol Sci, 14, 1822, 10.3390/ijms14011822 · DOI
  39. NM White, 2011, Metastamirs: a stepping stone towards improved cancer management, Nat Rev Clin Oncol, 8, 75, 10.1038/nrclinonc.2010.173 · DOI
  40. WC Cho, 2007, OncomiRs: the discovery and progress of microRNAs in cancers, Mol Cancer, 6, 60, 10.1186/1476-4598-6-60 · DOI
  41. YS Lee, 2009, MicroRNAs in cancer, Annu Rev Pathol, 4, 199, 10.1146/annurev.pathol.4.110807.092222 · DOI
  42. JA Foekens, 2008, Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer, Proc Natl Acad Sci U S A, 105, 13021, 10.1073/pnas.0803304105 · DOI
  43. J Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 · DOI
  44. S Volinia, 2013, Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer, Proc Natl Acad Sci U S A, 110, 7413, 10.1073/pnas.1304977110 · DOI · Paper page
  45. CC Pritchard, 2012, MicroRNA profiling: approaches and considerations, Nat Rev Genet, 13, 358, 10.1038/nrg3198 · DOI · Paper page
  46. CL Bartels, 2009, MicroRNAs: novel biomarkers for human cancer, Clin Chem, 55, 623, 10.1373/clinchem.2008.112805 · DOI
  47. M Shi, 2010, Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis, Cancer Metastasis Rev, 29, 785, 10.1007/s10555-010-9265-9 · DOI
  48. TO Nielsen, 2004, Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res, 10, 5367, 10.1158/1078-0432.CCR-04-0220 · DOI
  49. AC Wolff, 2007, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol, 25, 118, 10.1200/JCO.2006.09.2775 · DOI
  50. RC Gentleman, 2004, Bioconductor: open software development for computational biology and bioinformatics, Genome Biol, 5, R80, 10.1186/gb-2004-5-10-r80 · DOI
  51. BM Bolstad, 2003, A comparison of normalization methods for high density oligonucleotide array data based on variance and bias, Bioinformatics, 19, 185, 10.1093/bioinformatics/19.2.185 · DOI
  52. RA Irizarry, 2003, Summaries of Affymetrix GeneChip probe level data, Nucleic Acids Res, 31, e15, 10.1093/nar/gng015 · DOI
  53. RA Irizarry, 2003, Exploration, normalization, and summaries of high density oligonucleotide array probe level data, Biostatistics, 4, 249, 10.1093/biostatistics/4.2.249 · DOI · Paper page
  54. GK Smyth, 2004, Linear models and empirical bayes methods for assessing differential expression in microarray experiments, Stat Appl Genet Mol Biol, 3, Article3, 10.2202/1544-6115.1027 · DOI · Paper page
  55. R Breitling, 2004, Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments, FEBS Lett, 573, 83, 10.1016/j.febslet.2004.07.055 · DOI
  56. AM Molinaro, 2005, Prediction error estimation: a comparison of resampling methods, Bioinformatics, 21, 3301, 10.1093/bioinformatics/bti499 · DOI
  57. Efron B, Tibshirani R (1993) An introduction to the bootstrap. New York: Chapman & Hall. xvi, 436 p. p. · DOI · Paper page
  58. DF Ransohoff, 2004, Rules of evidence for cancer molecular-marker discovery and validation, Nat Rev Cancer, 4, 309, 10.1038/nrc1322 · DOI
  59. SD Hsu, 2011, miRTarBase: a database curates experimentally validated microRNA-target interactions, Nucleic Acids Res, 39, D163, 10.1093/nar/gkq1107 · DOI
  60. F Xiao, 2009, miRecords: an integrated resource for microRNA-target interactions, Nucleic Acids Res, 37, D105, 10.1093/nar/gkn851 · DOI
  61. P Shannon, 2003, Cytoscape: a software environment for integrated models of biomolecular interaction networks, Genome Res, 13, 2498, 10.1101/gr.1239303 · DOI · Paper page
  62. G Bindea, 2009, ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks, Bioinformatics, 25, 1091, 10.1093/bioinformatics/btp101 · DOI · Paper page
  63. G Bindea, 2013, CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data, Bioinformatics, 29, 661, 10.1093/bioinformatics/btt019 · DOI
  64. M Kutmon, 2013, CyTargetLinker: A Cytoscape App to Integrate Regulatory Interactions in Network Analysis, PLoS One, 8, e82160, 10.1371/journal.pone.0082160 · DOI
  65. C Blenkiron, 2007, MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype, Genome Biol, 8, R214, 10.1186/gb-2007-8-10-r214 · DOI
  66. VN Kristensen, 2012, Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling, Proc Natl Acad Sci U S A, 109, 2802, 10.1073/pnas.1108781108 · DOI
  67. H Dvinge, 2013, The shaping and functional consequences of the microRNA landscape in breast cancer, Nature, 497, 378, 10.1038/nature12108 · DOI
  68. AJ Lowery, 2009, MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer, Breast Cancer Res, 11, R27, 10.1186/bcr2257 · DOI
  69. I Van der Auwera, 2010, Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype, Br J Cancer, 103, 532, 10.1038/sj.bjc.6605787 · DOI
  70. S Romero-Cordoba, 2012, Identification and pathway analysis of microRNAs with no previous involvement in breast cancer, PLoS One, 7, e31904, 10.1371/journal.pone.0031904 · DOI
  71. EA Janssen, 2010, Biologic profiling of lymph node negative breast cancers by means of microRNA expression, Mod Pathol, 23, 1567, 10.1038/modpathol.2010.177 · DOI
  72. H Liu, 2010, Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma, BMC Syst Biol, 4, 51, 10.1186/1752-0509-4-51 · DOI
  73. H Takeshita, 2013, XB130, a new adaptor protein, regulates expression of tumor suppressive microRNAs in cancer cells, PLoS One, 8, e59057, 10.1371/journal.pone.0059057 · DOI
  74. HF Tu, 2012, The association between genetic polymorphism and the processing efficiency of miR-149 affects the prognosis of patients with head and neck squamous cell carcinoma, PLoS One, 7, e51606, 10.1371/journal.pone.0051606 · DOI
  75. F Wang, 2013, SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer, J Pathol, 229, 12, 10.1002/path.4078 · DOI
  76. Y Wang, 2012, MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer, PLoS One, 7, e41693, 10.1371/journal.pone.0041693 · DOI
  77. F Yu, 2010, Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells, Oncogene, 29, 4194, 10.1038/onc.2010.167 · DOI
  78. R Kumarswamy, 2012, MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer, Int J Cancer, 130, 2044, 10.1002/ijc.26218 · DOI
  79. S Caruso, 2012, MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?, Oncogenesis, 1, e32, 10.1038/oncsis.2012.33 · DOI
  80. H Lee, 2012, MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features, World J Surg Oncol, 10, 174, 10.1186/1477-7819-10-174 · DOI
  81. LX Yan, 2008, MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis, RNA, 14, 2348, 10.1261/rna.1034808 · DOI
  82. FG Rodriguez-Gonzalez, 2011, MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer, Breast Cancer Res Treat, 127, 43, 10.1007/s10549-010-0940-x · DOI
  83. S Ambs, 2008, Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer, Cancer Res, 68, 6162, 10.1158/0008-5472.CAN-08-0144 · DOI
  84. L Dylla, 2013, Growth-promoting role of the miR-106a∼363 cluster in Ewing sarcoma, PLoS One, 8, e63032, 10.1371/journal.pone.0063032 · DOI
  85. J Iqbal, 2012, Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis, Blood, 119, 4939, 10.1182/blood-2011-07-370122 · DOI
  86. S Landais, 2007, Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia, Cancer Res, 67, 5699, 10.1158/0008-5472.CAN-06-4478 · DOI
  87. L Castellano, 2009, The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response, Proc Natl Acad Sci U S A, 106, 15732, 10.1073/pnas.0906947106 · DOI
  88. F Rothe, 2011, Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer, PLoS One, 6, e20980, 10.1371/journal.pone.0020980 · DOI
  89. S Cascio, 2010, miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells, J Cell Physiol, 224, 242, 10.1002/jcp.22126 · DOI
  90. Z Lei, 2009, Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration, PLoS One, 4, e7629, 10.1371/journal.pone.0007629 · DOI
  91. AH Lund, 2010, miR-10 in development and cancer, Cell Death Differ, 17, 209, 10.1038/cdd.2009.58 · DOI
  92. Y Fang, 2010, MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro, Proc Natl Acad Sci U S A, 107, 13450, 10.1073/pnas.1002120107 · DOI
  93. H Huang, 2010, miR-10a contributes to retinoid acid-induced smooth muscle cell differentiation, J Biol Chem, 285, 9383, 10.1074/jbc.M109.095612 · DOI
  94. IP Pogribny, 2010, Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin, Int J Cancer, 127, 1785, 10.1002/ijc.25191 · DOI
  95. MF Segura, 2010, Melanoma MicroRNA signature predicts post-recurrence survival, Clin Cancer Res, 16, 1577, 10.1158/1078-0432.CCR-09-2721 · DOI
  96. Y Wei, 2013, The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis, Circulation, 127, 1609, 10.1161/CIRCULATIONAHA.112.000736 · DOI
  97. GN Naumov, 2006, Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch, Cell Cycle, 5, 1779, 10.4161/cc.5.16.3018 · DOI
  98. JA Aguirre-Ghiso, 2007, Models, mechanisms and clinical evidence for cancer dormancy, Nat Rev Cancer, 7, 834, 10.1038/nrc2256 · DOI
  99. N McCarthy, 2013, A perivascular niche can promote dormancy, Nat Rev Cancer, 13, 441, 10.1038/nrc3561 · DOI
  100. C Camps, 2008, hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer, Clin Cancer Res, 14, 1340, 10.1158/1078-0432.CCR-07-1755 · DOI
  101. S Volinia, 2012, Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA, Proc Natl Acad Sci U S A, 109, 3024, 10.1073/pnas.1200010109 · DOI
  102. 2002, Microarray data normalization and transformation, Nat Genet, 32

Cited by

Sorted by citations

See all 67

Metadata

Authors
Pérez-Rivas, L. G., Jerez, J. M., Carmona, R., de Luque, V., Vicioso, L., Claros, M. G., Viguera, E., Pajares, B., Sánchez, A., Ribelles, N., Alba, E., & Lozano, J.
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2014-03-14
Volume
9
Issue
3
Pages
e91884
ISSN
1932-6203
DOI
10.1371/journal.pone.0091884
PMC
PMC3954835
Cited by
67
References
2
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review